| Literature DB >> 31403240 |
Caner Süsal1, Güclü Aykut1, Christian Morath2, Alexander Fichtner3, Christian Unterrainer1, Sabine Scherer1, Thuong H Tran1, Arianeb Mehrabi4, Martin Zeier2, Burkhard Tönshoff3.
Abstract
Monitoring of donor-specific HLA antibodies (DSA) has become part of the clinical routine in kidney transplantation. This paper gives a brief overview on data from the Collaborative Transplant Study (CTS) and the Heidelberg Transplant Center on the clinical relevance of post-transplant DSA monitoring in patients undergoing renal transplantation. The obtained findings underline the importance of DSA monitoring in the post-operative course in immunologically high-risk patients and patients with deterioration of graft function. Especially in patients with a pre-activated immune system, a gap in the immunosuppressive therapy appear to lead to persistence, reappearance or de novo occurrence of strong, complement-activating DSA, resulting in severe antibody-mediated rejection (AMR) and, without timely intervention, in AMR-related graft loss.Entities:
Keywords: C1q; antibody-mediated rejection; donor-specific antibodies; graft rejection; graft survival; kidney transplantation; sCD30; tacrolimus; under-immunosuppression
Mesh:
Substances:
Year: 2019 PMID: 31403240 DOI: 10.1111/tan.13665
Source DB: PubMed Journal: HLA ISSN: 2059-2302 Impact factor: 4.513